Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott

Profit jumps 12% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott

4Q Revenues: $10.4 billion (+4%)

4Q Earnings: $1.6 billion (+12%)

FY Revenues: $38.9 billion (+11%)

FY Earnings: $4.7 billion (+2%)

Comments: Proprietary Pharmaceutical sales in the quarter were $4.8 billion (+7%), and for the year grew 11% to $17.0 billion. Humira sales were $2.2 billion in the quarter (+16%), and $7.9 billion for the year (+21%). Trilipix/TriCor sales were down 4% to $483 million in the quarter and up 6% to $1.7 billion for the year. Kaletra sales were down 16% to $288 million in the quarter and down 7% to $1.2 billion for the year. Niaspan sales were down 10% to $258 million in the quarter and up 5% to $976 million for the year. Nutritionals sales were $1.6 billion in the quarter and $6.0 billion for the year, both up 9%. Established Pharmaceuticals, which includes sales of branded generics outside the U.S., declined 5% in the quarter to $1.4 billion and grew 20% to $5.4 billion for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters